Abstract 4822
Background
Local advanced nasopharyngeal carcinoma (NPC) patients receiving neoadjuvant chemotherapy (NACT) and concurrent chemoradiotherapy (CCRT) suffered from malnutrition and declining quality of life. We investigate the impact of prophylactic or reactive nutritional support on nutritional status and quality of life.
Methods
Enrolled patients were randomly assigned to receive prophylactic (group A) or reactive nutrition intervention (group B). Group A was supported with enteral nutrition beyond daily diet from the beginning of radiotherapy (RT). Group B was treated with conventional diet guidance, appropriate nutritional intervention will be given when needed. Patients were asked to complete the EORTC QLQ-C30 and QLQ-H&N35 questionnaires at the baseline, before, during and after CCRT. Weight and hematological indexes were also collected. Statistical analyses are using SPSS 18.0.
Results
From October 2016 to May 2018, 114 patients were randomly assigned into the group A (n = 58) and B (n = 56). 80.7% of patients completed concurrent chemotherapy (A vs B = 90% vs 71%, P = 0.013, 95%IC=0.038-0.326). All patients experienced weight loss during the CCRT. Comparing to baseline, the rate of weight loss ≥5% before, during, at the end of RT and 1- and 3-month after RT were 3.5%, 28.9%, 29.8%, 64.7% and 33.2%. After treatment, Total serum protein and albumin of group A were better than B (68.7±6.31 vs 65.6±5.27 g/L, p = 0.003 and 41.86±4.05 vs 39.52±3.93 g/L, p = 0.001). Incidence of anemia at these times were 2%,37%,53%,55% and 19%. But no differences were found in two groups. Global health status scores in QLQ-C30 and QLQ-H&N35 decreased during NAT and CCRT. After RT, quality of life issues significant improved at the 1-and 3-months follow-up comparing to the end of treatment (65.34 and 76.4 vs 39.8, p = 0.00). But no statistical advantages of QoL were found in Patients in group A except feeling ill.
Conclusions
The nutrition status and QoL of NPC patients decreased during treatment. Though prophylactic nutritional intervention can enhance the completion of concurrent chemotherapy and keep the plasma protein stable, but it has no advantage in weight loss and quality of life except feeling ill.
Clinical trial identification
NCT02948699.
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
Nutricia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3839 - Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations.
Presenter: Tomasz Wróbel
Session: Poster Display session 3
Resources:
Abstract
3842 - Effect of docetaxel-resistance on the reactivity of prostate cancer cells to metformin
Presenter: Jessica Catapano
Session: Poster Display session 3
Resources:
Abstract
5198 - Cell plasticity and taxanes resistance in metastatic prostate cancer: ESRP1 as a predictive biomarker of taxane response
Presenter: Natalia Jimenez
Session: Poster Display session 3
Resources:
Abstract
2981 - Effect of Selumetinib plus AZD8186 treatment on Cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines
Presenter: Vicenc Ruiz de Porras
Session: Poster Display session 3
Resources:
Abstract
2779 - Anti-tumor activity of cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, in pancreatic ductal adenocarcinoma cells
Presenter: Majid Momeny
Session: Poster Display session 3
Resources:
Abstract
1782 - The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy
Presenter: Han-chung Wu
Session: Poster Display session 3
Resources:
Abstract
1322 - Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients
Presenter: Jens Hahne
Session: Poster Display session 3
Resources:
Abstract
1579 - Serum exosomal microRNA-199b-5p as a novel circulating biomarker to predict response of preoperative chemoradiotherapy for locally advanced rectal cancer
Presenter: Dong Won Baek
Session: Poster Display session 3
Resources:
Abstract
1761 - Live biobank of patient-derived organoids from Thai colorectal cancer patients enables clinical outcome prediction
Presenter: Pariyada Tanjak
Session: Poster Display session 3
Resources:
Abstract
3542 - The biological implications of PDCD6 dysregulation in colorectal cancer
Presenter: Romina Briffa
Session: Poster Display session 3
Resources:
Abstract